Everolimus in pancreatic neuroendocrine carcinomas G3

Francesco Panzuto, Maria Rinzivillo, Francesca Spada, Lorenzo Antonuzzo, Toni Ibrahim, Davide Campana, Nicola Fazio, Gianfranco Delle Fave

Research output: Contribution to journalArticlepeer-review


Objective: The aim of this study was to investigate everolimus efficacy in well-moderately differentiated pancreatic NEC (pNEC) G3. Methods: This was a retrospective analysis of patients with pNEC G3 and Ki67 20% to 55% treated with everolimus. Results: Fifteen patients with median Ki67 30%and Eastern Cooperative Oncology Group performance status 0 to 1 were evaluated. Of these, 4 patients received everolimus as first-line treatment, whereas 11 had been pretreated with chemotherapy or peptide receptor radionuclide therapy. Median progression-free survival was 6 months, and median overall survival was 28 months. Eleven patients achieved disease stabilization (DS) at 3 month follow-up. Six patients (40%) maintained DS for at least 12 months. Three of 4 patients who received everolimus as first-line therapy had sustained DS (progression-free survival, 12, 17, and 22 months). The safety profile was consistent with that previously reported, with adverse events occurring in 9 patients (66.7%). Conclusions: This study suggests that everolimus is active in pNECG3with well-moderately differentiated morphology andKi67 less than 55%, inwhich more toxic systemic chemotherapy is, to date, the only available treatment.

Original languageEnglish
Pages (from-to)302-305
Number of pages4
Issue number3
Publication statusPublished - Mar 1 2017


  • Everolimus
  • Grading
  • Neuroendocrine carcinomas
  • Pancreas

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology


Dive into the research topics of 'Everolimus in pancreatic neuroendocrine carcinomas G3'. Together they form a unique fingerprint.

Cite this